BIODEXA PHARMACEUTICALS PLC (BDRX)
Institutional ownership reported to the SEC as of Q2 2026, across 12 quarters.
Institutions report 16,569 shares against 225,817,808,922 outstanding. Shares only - option lines are excluded, which is why this can be compared with the company at all. The count comes from the cover page of the company's own most recent report, so it is dated when that was filed rather than at quarter end. Share count carried from an earlier filing (cy2025q4i).
Options share is the part of reported value carried in derivative lines rather than shares. A high figure means institutions are expressing a view on this security without owning much of it.
Holders
| Filer | Value | Shares | Their book | Held | Change |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | $43.1K | 14,809 | 0.00% | new | NEW |
| GAMMA Investing LLC | $3.5K | 1,203 | 0.00% | new | NEW |
| Allied Private Wealth LLC | $1.3K | 489 | 0.00% | new | FIRST |
| SBI Securities Co., Ltd. | $84 | 29 | 0.00% | 2q | -80.8% |
| UBS Group AG | $73 | 25 | 0.00% | new | NEW |
| Hilton Head Capital Partners, LLC | $17 | 6 | 0.00% | new | NEW |
| Caitong International Asset Management Co., Ltd | $15 | 5 | 0.00% | new | NEW |
| RHUMBLINE ADVISERS | $8 | 3 | 0.00% | 4q | -84.2% |
Five percent filings
Anyone crossing 5% of a company must say so within days - far sooner than the next quarterly holdings report. A 13D declares an intent to influence the company; a 13G is the passive version. See all activist filings →
| Filed | Form | Filer | % of class |
|---|---|---|---|
| 2026-08-14 | 13G/A | Armistice Capital, LLCwith 1 co-filers | 10.0% |
Quarter by quarter
Coverage begins with the quarter ending 2018-12-31. Earlier filings exist only as occasional late amendments, too sparse to describe a market, so they are not shown.
| Quarter | Holders | Value | Shares | New | Added | Trimmed | Options |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 8 | $48.1K | 16,569 | 5 | 0 | 2 | 0.0% |
| Q1 2026 | 8 | $228.1K | 369,101 | 2 | 2 | 3 | 0.0% |
| Q4 2025 | 7 | $668.9K | 294,690 | 2 | 2 | 2 | 0.0% |
| Q3 2025 | 4 | $55.8K | 8,397 | 4 | 0 | 0 | 0.0% |
| Q2 2025 | 4 | $17.0K | 19,666 | 0 | 2 | 2 | 0.0% |
| Q1 2025 | 6 | $28.1K | 21,314 | 2 | 2 | 0 | 0.0% |
| Q4 2024 | 4 | $29.3K | 7,242 | 3 | 0 | 0 | 0.0% |
| Q3 2024 | 6 | $87.3K | 309,668 | 0 | 4 | 1 | 0.0% |
| Q2 2024 | 11 | $103.6K | 115,671 | 6 | 2 | 3 | 0.0% |
| Q1 2024 | 5 | $31.3K | 19,321 | 0 | 3 | 0 | 0.0% |
| Q4 2023 | 6 | $138.2K | 51,995 | 2 | 3 | 0 | 0.0% |
| Q3 2023 | 5 | $58.9K | 12,098 | 5 | 0 | 0 | 0.0% |